MG
RNAZ icon

Marex Group’s TransCode Therapeutics RNAZ Stock Holding History

Marex Group’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-453
Closed -$6.28K – 883
2025
Q1 		$6.28K Buy
+453
New +$58K ﹤0.01% 675

Other funds holding RNAZ

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SC
SouthState Corp Winter Haven, Florida $2.14B AUM 18.39% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Marex Group's RNAZ Position: Q2 2025 in Review

Marex Group sold out of TransCode Therapeutics (RNAZ) in Q2 2025, closing a stake of 453 shares — an estimated $6.28K sold.

Marex Group first reported a position in RNAZ in Q1 2025 and held it in 1 quarter. The position peaked at $6.28K in Q1 2025. 9 funds tracked by Wall St. Rank hold RNAZ as of Q2 2025.

  • Marex Group reported no remaining TransCode Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Marex Group sold 453 TransCode Therapeutics shares in Q2 2025, an estimated $6.28K.
  • Marex Group first reported a position in TransCode Therapeutics in Q1 2025 and held it in 1 quarter.
  • Marex Group's TransCode Therapeutics position peaked at $6.28K in Q1 2025.
  • 9 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2025.

Based on Marex Group's 13F filing for Q2 2025, filed 19 Aug 2025.